Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Felicia Ceban, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 841-852
Open Access | Times Cited: 22

Showing 22 citing articles:

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 84
Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
Octavian Vasiliu
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 46
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Konstantinos Ν. Fountoulakis, Athanasios Saitis, Alan F. Schatzberg
American Journal of Psychiatry (2025)
Closed Access | Times Cited: 11
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Zhibin Wang, Lili Jiang, Wei Ma, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 3
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database
Ying Jiang, Zhiqiang Du, Yuan Shen, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023)
Closed Access | Times Cited: 39
The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni, et al.
Brain Sciences (2023) Vol. 13, Iss. 6, pp. 909-909
Open Access | Times Cited: 37
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
John H. Krystal, Alfred P. Kaye, Sarah Jefferson, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 35
The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
Giacomo d’Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, et al.
Journal of Affective Disorders (2023) Vol. 348, pp. 314-322
Closed Access | Times Cited: 26
Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis
Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 10
Clinical investigations of compounds targeting metabotropic glutamate receptors
Jeffrey M. Witkin, Kamal Prakash Pandey, Jodi L. Smith
Pharmacology Biochemistry and Behavior (2022) Vol. 219, pp. 173446-173446
Closed Access | Times Cited: 26
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
Neuropharmacology (2022) Vol. 223, pp. 109299-109299
Closed Access | Times Cited: 24
Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression
Jian-Qiang Tan, Li-Mei Gu, Yanling Zhou, et al.
Frontiers in Psychiatry (2025) Vol. 16
Open Access
Ketamine, benzoate, and sarcosine for treating depression
Yu‐Jung Cheng, Chieh‐Hsin Lin, Hsien‐Yuan Lane
Neuropharmacology (2022) Vol. 223, pp. 109351-109351
Closed Access | Times Cited: 13
What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Judy Hope, David Copolov, John Tiller, et al.
Australasian Psychiatry (2023) Vol. 31, Iss. 6, pp. 841-845
Open Access | Times Cited: 5
Intranasal Esketamine for Patients with Major Depressive Disorder: A Systematic Review and Meta-Analysis
Soroush Oraee, Mohammadreza Alinejadfard, Hossein Golsorkh, et al.
Journal of Psychiatric Research (2024) Vol. 180, pp. 371-379
Closed Access | Times Cited: 1
La kétamine : un neuropsychotrope au mécanisme d’action innovant
Jean‐Philippe Guilloux, Thi Mai Loan Nguyen, Alain M. Gardier
Biologie Aujourd hui (2023) Vol. 217, Iss. 3-4, pp. 133-144
Closed Access | Times Cited: 3
Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?
Harry Griffiths
British Journal of Pain (2023) Vol. 17, Iss. 5, pp. 457-467
Open Access | Times Cited: 2
Use of intranasal esketamine in the treatment of treatment-resistant depression: A case report
Stefan Jerotić, Joko Poleksić, Maja Ivković, et al.
Srpski medicinski casopis Lekarske komore (2024) Vol. 5, Iss. 2, pp. 239-247
Open Access
Zweitschrittverfahren in der antidepressiven Pharmakotherapie
Marlene Krabs, Tom Bschor, Jonathan Henssler, et al.
Der Nervenarzt (2024)
Closed Access
Effects of Ketamine and Esketamine on Cognitive Functions in Treatment-Resistant Depression
Mahir Mutlu, Çağrı Öven, Bilge Sena Kurt, et al.
Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry (2024) Vol. 17, Iss. 3, pp. 493-506
Open Access
Psychofarmakologia – Quo vadis?
Janusz Rybakowski
Nauka (2023), pp. 87-106
Open Access
The use of ketamine and esketamine in psychiatry: now and beyond
José Carlos Appolinário, Antônio Egídio Nardi
Jornal Brasileiro de Psiquiatria (2022) Vol. 71, Iss. 3, pp. 164-165
Open Access
Page 1

Scroll to top